These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 25438467)
1. A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. Galeazzi M; Bazzichi L; Sebastiani GD; Neri D; Garcia E; Ravenni N; Giovannoni L; Wilton J; Bardelli M; Baldi C; Selvi E; Iuliano A; Minisola G; Caporali R; Prisco E; Bombardieri S Isr Med Assoc J; 2014 Oct; 16(10):666. PubMed ID: 25438467 [No Abstract] [Full Text] [Related]
2. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials. Parker CT; Mewshaw E; Dennis GJ J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316 [No Abstract] [Full Text] [Related]
3. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926 [TBL] [Abstract][Full Text] [Related]
4. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435 [TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067 [TBL] [Abstract][Full Text] [Related]
6. Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis. Scoville CD Clin Exp Rheumatol; 2001; 19(3):360-1. PubMed ID: 11407104 [No Abstract] [Full Text] [Related]
7. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886 [No Abstract] [Full Text] [Related]
8. Self-injection of gold and methotrexate. Arthur V; Jubb R; Homer D J Rheumatol; 2001 Jan; 28(1):212. PubMed ID: 11196528 [No Abstract] [Full Text] [Related]
9. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Hameed B; Jones H Int J Rheum Dis; 2010 Oct; 13(4):e83-4. PubMed ID: 21199461 [No Abstract] [Full Text] [Related]
10. The issue of bioavailability of oral low dose methotrexate: should we choose only 10 mg of MTX a week in conjunction with anti-TNF therapy? Zeidler H Ann Rheum Dis; 2014 Aug; 73(8):e50. PubMed ID: 24764450 [No Abstract] [Full Text] [Related]
11. [Subcutaneous self-administration of methotrexate in rheumatoid arthritis]. Huisman AM; Schouten JP; van Paassen HC; Wouters JM; Jacobs JW Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1564-5. PubMed ID: 8765767 [No Abstract] [Full Text] [Related]
12. [Treatment of chronic polyarthritis with methotrexate 1994--a review]. Rau R Z Rheumatol; 1994; 53(4):199-229. PubMed ID: 7975933 [No Abstract] [Full Text] [Related]
13. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis. Koduri GM; Mukhtyar C Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739 [No Abstract] [Full Text] [Related]
14. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab. Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF; Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349 [No Abstract] [Full Text] [Related]
15. [What methotrexate dose is optimal in combination with adalimumab?]. Ranft D Med Monatsschr Pharm; 2015 Apr; 38(4):148-9. PubMed ID: 26364386 [No Abstract] [Full Text] [Related]
16. [Methotrexate and folates in rheumatoid arthritis]. Endresen GK; Husby G Tidsskr Nor Laegeforen; 1999 Feb; 119(4):534-7. PubMed ID: 10081378 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial. Furuzawa-Carballeda J; Cabral AR; Zapata-Zuñiga M; Alcocer-Varela J J Rheumatol; 2003 Feb; 30(2):256-9. PubMed ID: 12563677 [TBL] [Abstract][Full Text] [Related]
18. Parenteral methotrexate for the treatment of rheumatoid arthritis. Yazici Y; Bata Y Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041 [TBL] [Abstract][Full Text] [Related]
19. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM; Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]